Please wait. Loading...

EIAgen HBe Ab&Ag



brief description

Hepatitis B is a disease caused by viral infection. The route of infection can be improper needle puncture, blood transfusion or even by taking contaminated food or water. Hepatitis B (HB) has become a significant problem for public health management. Almost one in every ten adults, who have been infected by Hepatitis B Virus (HBV), develops some form of chronic liver disease and becomes a long-term carrier of HBV. Screening for HB is, therefore, urgently needed. HB is an immune disease. Invasion of the human body by HBV induces auto-immune reactions which damage the liver. The components of the virus (antigens) and the host responses (antibodies), the so-called immunologic markers have often been used as diagnostic tools. There are six immunologic markers of HBV: HBsAg, HBcAg, HBeAg and their respective antibodies. HBeAg is detected only in HBsAg positive serum. Its presence coincides with the rapid propagation of HBV and high infectivity. It is also a marker of questionable prognosis including the development of chronic Hepatitis. On the contrary, anti-HBe represents minimum viral replication and greatly reduced infectivity. When a patient changes from HBeAg to its antibody, he or she is likely to enter convalescent stage. But it is also possible that patients with anti-HBe are long-term carriers of HBV. Nevertheless, patients with anti-HBe generally have optimistic prognosis.

intended use

Enzyme ImmunoAssay (ELISA) for the determination of Hepatitis B Virus "e" Antigen and Antibody in human plasma and sera.

© 2015 LENCO HELLAS S.A. - All rights reserved.